Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Always a pleasure catching up with the brilliant colleague and great friend Dr. Johanna Bendell – few people can light up a conversation on oncology drug development the way she does.
We covered it all: new targets, new drugs, new strategies and the future that’s coming at us fast.
My Pre- American Society of Clinical Oncology (ASCO) ASCO 26 is off to a great start.
Nothing better than discussions with a world‑class drug developer + clinical trialist who’s shaping where the field goes next at Pfizer.”
Other articles featuring Vivek Subbiah on OncoDaily.